达格列净与2型糖尿病的心血管结局
DECLARE-TIMI 58随机对照试验将17,160例2型糖尿病合并或高危动脉粥样硬化性心血管疾病患者随机分配至达格列净或安慰剂组,中位随访4.2年。主要安全性终点MACE达到预设非劣效标准;主要疗效终点MACE未显著降低(8.8% vs 9.4%,HR 0.93,95%CI 0.84-1.03,P=0.17),但心血管死亡或心衰住院复合终点显著降低(4.9% vs 5.8%,HR 0.83,95%CI 0.73-0.95,P=0.005),主要反映心衰住院减少(HR 0.73,95%CI 0.61-0.88)。肾脏复合终点降低(4.3% vs 5.6%,HR 0.76,95%CI 0.67-0.87),全因死亡无显著差异。达格列净组糖尿病酮症酸中毒和生殖器感染更常见。
要点
- 达格列净对MACE达到非劣效(95%CI上限<1.3,非劣效P<0.001),未增加主要不良心血管事件风险。
- 心血管死亡或心衰住院复合终点:达格列净组4.9% vs 安慰剂组5.8%(HR 0.83,95%CI 0.73-0.95,P=0.005),主要因心衰住院减少(HR 0.73,95%CI 0.61-0.88)。
- 肾脏复合终点:达格列净组4.3% vs 安慰剂组5.6%(HR 0.76,95%CI 0.67-0.87)。
- 糖尿病酮症酸中毒更常见:达格列净组0.3% vs 安慰剂组0.1%(P=0.02)。
- 导致停药或被视为严重不良事件的生殖器感染更常见:达格列净组0.9% vs 安慰剂组0.1%(P<0.001)。
适用人群与场景
- 2型糖尿病合并动脉粥样硬化性心血管疾病或存在动脉粥样硬化性心血管疾病风险的患者,共17,160例,其中10,186例无动脉粥样硬化性心血管疾病。
研究设计与关键结果
- DECLARE-TIMI 58随机对照试验,纳入17,160例2型糖尿病合并或高危动脉粥样硬化性心血管疾病患者,随机分配至达格列净或安慰剂组,中位随访4.2年。
- 主要安全性终点MACE(心血管死亡、心肌梗死或缺血性卒中复合终点):达格列净达到预设非劣效标准(95%CI上限<1.3,非劣效P<0.001)。
- 主要疗效终点MACE:达格列净组8.8% vs 安慰剂组9.4%(HR 0.93,95%CI 0.84-1.03,P=0.17),未达统计学显著。
- 心血管死亡或心衰住院复合终点:达格列净组4.9% vs 安慰剂组5.8%(HR 0.83,95%CI 0.73-0.95,P=0.005);其中心衰住院HR 0.73(95%CI 0.61-0.88),心血管死亡HR 0.98(95%CI 0.82-1.17),组间无显著差异。
- 肾脏复合终点(eGFR较基线下降≥40%且eGFR<60 ml/min/1.73m²、新发终末期肾病或肾脏/心血管原因死亡):达格列净组4.3% vs 安慰剂组5.6%(HR 0.76,95%CI 0.67-0.87)。
- 全因死亡:达格列净组6.2% vs 安慰剂组6.6%(HR 0.93,95%CI 0.82-1.04)。
- 不良事件:糖尿病酮症酸中毒达格列净组0.3% vs 安慰剂组0.1%(P=0.02);导致停药或被视为严重不良事件的生殖器感染达格列净组0.9% vs 安慰剂组0.1%(P<0.001)。
证据类型、等级与局限
- 证据类型:随机对照试验(DECLARE-TIMI 58,ClinicalTrials.gov NCT01730534),由AstraZeneca资助。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对2型糖尿病合并或高危动脉粥样硬化性心血管疾病患者,达格列净未增加MACE风险,但未显著降低MACE发生率。
- 达格列净可降低心血管死亡或心衰住院复合终点(HR 0.83,95%CI 0.73-0.95),主要源于心衰住院减少(HR 0.73,95%CI 0.61-0.88)。
- 使用达格列净时需注意糖尿病酮症酸中毒(0.3% vs 0.1%,P=0.02)和导致停药或严重不良事件的生殖器感染(0.9% vs 0.1%,P<0.001)风险增加。
- 原文未据此给出推荐。
指南或共识出处
- DECLARE-TIMI 58试验,N Engl J Med发表,AstraZeneca资助,ClinicalTrials.gov注册号NCT01730534。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is undefined.
METHODS: We randomly assigned patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease to receive either dapagliflozin or placebo. The primary safety outcome was a composite of major adverse cardiovascular events (MACE), defined as cardiovascular death, myocardial infarction, or ischemic stroke. The primary efficacy outcomes were MACE and a composite of cardiovascular death or hospitalization for heart failure. Secondary efficacy outcomes were a renal composite (≥40% decrease in estimated glomerular filtration rate to <60 ml per minute per 1.73 m2 of body-surface area, new end-stage renal disease, or death from renal or cardiovascular causes) and death from any cause.
RESULTS: We evaluated 17,160 patients, including 10,186 without atherosclerotic cardiovascular disease, who were followed for a median of 4.2 years. In the primary safety outcome analysis, dapagliflozin met the prespecified criterion for noninferiority to placebo with respect to MACE (upper boundary of the 95% confidence interval [CI], <1.3; P<0.001 for noninferiority). In the two primary efficacy analyses, dapagliflozin did not result in a lower rate of MACE (8.8% in the dapagliflozin group and 9.4% in the placebo group; hazard ratio, 0.93; 95% CI, 0.84 to 1.03; P=0.17) but did result in a lower rate of cardiovascular death or hospitalization for heart failure (4.9% vs. 5.8%; hazard ratio, 0.83; 95% CI, 0.73 to 0.95; P=0.005), which reflected a lower rate of hospitalization for heart failure (hazard ratio, 0.73; 95% CI, 0.61 to 0.88); there was no between-group difference in cardiovascular death (hazard ratio, 0.98; 95% CI, 0.82 to 1.17). A renal event occurred in 4.3% in the dapagliflozin group and in 5.6% in the placebo group (hazard ratio, 0.76; 95% CI, 0.67 to 0.87), and death from any cause occurred in 6.2% and 6.6%, respectively (hazard ratio, 0.93; 95% CI, 0.82 to 1.04). Diabetic ketoacidosis was more common with dapagliflozin than with placebo (0.3% vs. 0.1%, P=0.02), as was the rate of genital infections that led to discontinuation of the regimen or that were considered to be serious adverse events (0.9% vs. 0.1%, P<0.001).
CONCLUSIONS: In patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease, treatment with dapagliflozin did not result in a higher or lower rate of MACE than placebo but did result in a lower rate of cardiovascular death or hospitalization for heart failure, a finding that reflects a lower rate of hospitalization for heart failure. (Funded by AstraZeneca; DECLARE-TIMI 58 ClinicalTrials.gov number, NCT01730534 .).
参考来源
- Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2018. PMID: 30415602. doi:10.1056/NEJMoa1812389
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。